References
- GaffenSLStructure and signalling in the IL-17 receptor familyNat Rev Immunol20099855656719575028
- HotAZrioualSTohM-LLeniefVMiossecPIL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytesAnn Rheum Dis201170234134821109515
- StarkMAHuoYBurcinTLMorrisMAOlsonTSLeyKPhagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17Immunity200522328529415780986
- CuaDJTatoCMInnate IL-17-producing cells: the sentinels of the immune systemNat Rev Immunol201010747948920559326
- MiossecPKornTKuchrooVKInterleukin-17 and type 17 helper T cellsN Engl J Med2009361988889819710487
- CypowyjSPicardCMarodiLCasanovaJLPuelAImmunity to infection in IL-17-deficient mice and humansEur J Immunol20124292246225422949323
- Hernandez-SantosNGaffenSLTh17 cells in immunity to Candida albicansCell Host Microbe201211542543522607796
- GaffenSLJainRGargAVCuaDJThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingNat Rev Immunol201414958560025145755
- GriffithsCEMReichKLebwohlMUNCOVER-2 and UNCOVER-3 InvestigatorsComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
- LangleyRGElewskiBELebwohlMERASURE Study GroupFIXTURE Study GroupSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
- VasserotAPDickinsonCDTangYHuseWDManchesterKSWatkinsJDOptimization of protein therapeutics by directed evolutionDrug Discov Today20038311812612568781
- LabrijnAFBuijsseAOvan den BremerETTherapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivoNat Biotechnol200927876777119620983
- BloomJWMadanatMSMarriottDWongTChanSYIntrachain disulfide bond in the core hinge region of human IgG4Protein Sci1997624074159041643
- LiuSSongXChrunykBACrystal structures of interleukin 17A and its complex with IL-17 receptor ANat Commun20134188823695682
- ChanACCarterPJTherapeutic antibodies for autoimmunity and inflammationNat Rev Immunol201010530131620414204
- HardingFASticklerMMRazoJDuBridgeRBThe immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsMAbs20102325626520400861
- LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med2012366131190119922455413
- KruegerJGFretzinSSuarez-FarinasMIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJ Allergy Clin Immunol20121301145.e154.e22677045
- GenoveseMCGreenwaldMChoCSA phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsArthritis Rheumatol20146671693170424623718
- LangleyRGRichPMenterAImprovement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol20152991763177025693783
- GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
- BaetenDBaraliakosXBraunJAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialLancet201338299061705171324035250